Article Sidebar

Submitted
1 September 2020
Accepted
28 September 2021
Published
7 December 2021
Download
PDF
Statistic
Read Counter : 1160 Download : 1296

Main Article Content

Abstract

Highlight:

  1. Differences in the efficacy of CYD-TDV versus the other TAK-003 and TV003/TV005 were discussed.
  2. One licensed dengue vaccine is CYD-TDV (Dengvaxia).
 

Abstract:

Dengue fever is the most common tropical disease, but there still remains no specific therapy that can overcome it. Special attention needs to be paid to this disease, because there were large increases in incidence in the last decade. As an effective preventive strategy, finding a new vaccine for dengue fever with higher potentiation and efficacy is highly necessary to stop dengue transmission especially in the endemic area. Vaccine triggers an immune response, so that it can create a robust immune response when infected. Nowadays, there is only one licensed dengue vaccine that is CYD-TDV (Dengvaxia). However, this vaccine still has many weaknesses, namely its dependency on the serostatus of the recipient. There are also other dengue vaccines that are in ongoing clinical testing and have promising results, TDV (TAK-003) and TV003/TV005. These three vaccines are live attenuated vaccines with various results. This review discussed differences in the efficacy of CYD-TDV against the other TAK-003 and TV003/TV005; considering the known and unknown various factors.

Keywords

Live attenuated dengue vaccines CYD-TDV TAK-003 TV003/TV005 tropical disease

Article Details

License

Copyright (c) 2021 Yoseph Jeffry Hertanto, Bernadette Dian Novita

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

How to Cite
Hertanto, Y. J., & Novita, B. D. (2021). Efficacy of Live Attenuated Dengue Vaccines: CYD-TDV, TDV (TAK-003), and TV003/TV005. Folia Medica Indonesiana, 57(4), 365–371. https://doi.org/10.20473/fmi.v57i4.21741
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Arredondo-Garcí­a JL, Hadinegoro SR, Reynales H, et al (2018). Four-year safety follow-up of the tetravalent dengue vaccine ef fi cacy randomized controlled trials in Asia and Latin America. Clin Microbiol Infect 24, 755-63.
  2. Biswal S, Borja-tabora C, Vargas LM, et al (2020). Efficacy of a tetravalent dengue vaccine in healthy children aged 4 – 16 years: A randomised, placebo-controlled, phase 3 trial. Lancet 395, 1423-1433.
  3. Biswal S, Reynales H, Saez-Llorens X, et al (2019). Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N Engl J Med 381, 2009-2019.
  4. Collins MH, Metz SW (2017). Progress and works in progress: Update on flavivirus vaccine Development. Clin Ther 39, 1519-36.
  5. Collins MH, Metz SW, Carolina N (2017). Progress and works in progress: Update on flavivirus vaccine development. Clin Ther 39, 1519-36.
  6. Da Silveira LTC, Tura B, Santos M (2019). Systematic review of dengue vaccine efficacy. BMC Infect Dis 19, 1-8.
  7. Deng S, Yang X, Wei Y, et al (2020). A review on dengue vaccine development. Vaccines 8, 1-13.
  8. Durbin AP, Gubler DJ (2019). What is the prospect of a safe and effective dengue vaccine for travellers? J Travel Med 26, 1-2.
  9. Hadinegoro SR, Arredondo"‘Garcí­a JL, Capeding MR, et al (2015). Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 373, 1195-206.
  10. Harenberg A, Montfort AD, Jantet-blaudez F (2016). Cytokine profile of children hospitalized with virologically-confirmed dengue during two phase III vaccine efficacy trials. PLoS Negl Trop Dis 10, 1-17.
  11. Kallas EG, Precioso AR, Palacios R, et al (2020). Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: A two-step, double-blind, randomised placebo-controlled phase 2 trial. Lancet Infect Dis 20, 839-850.
  12. Kirkpatrick BD, Durbin AP, Pierce KK, et al (2015). Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J Infect Dis 212, 702-710.
  14. Kirkpatrick BD, Whitehead SS, Pierce KK, et al (2016). The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model. Sci Transl Med 8, 330-336.
  15. Macias A, Ruiz-Palacios G, Ramos-Castaneda J (2020). Combine dengue vaccines to optimize effectiveness. Vaccine 38, 4801-4804.
  17. Murray NEA, Quam MB, Wilder-Smith A (2013). Epidemiology of dengue: Past, present and future prospects. Clin Epidemiol 5, 299-309.
  18. Pinheiro-Michelsen JR, Souza RdSO, Santana IVR, et al (2020). Anti-dengue Vaccines: From development to clinical trials. Front Immunol 11, 1-18.
  19. Plotkin SA (2020). Dengue vaccine - A double-edged sword. J Pediatric Infect Dis Soc 9, 107-9.
  20. Prompetchara E, Ketloy C, Thomas SJ, et al (2020). Dengue vaccine: Global development update. Asian Pacific J Allergy Immunol 38, 178-185.
  21. Sáez-llorens X, Tricou V, Yu D, et al (2017). Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2 – 17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study. Lancet Infect Dis 2099, 1-9.
  22. Sáez-llorens X, Tricou V, Yu D, et al (2017). Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: Interim results from a phase 2, randomised, placebo-controlled study. Lancet Infect Dis 3099, 1-11.
  23. Sirivichayakul C, Barranco-santana EA, Esquilin-rivera I, et al (2015). Safety and immunogenicity of a tetravalent dengue vaccine (TDV) in healthy children and adults in endemic regions: A randomized, placebo-controlled Phase 2 study. J Infect Dis 213, 1562-1572.
  24. Sirivichayakul C, Barranco-santana EA, Rivera IE, et al (2020). Long-term safety and immunogenicity of a tetravalent dengue vaccine candidate in children and adults: a randomized, placebo-controlled, phase 2 study. J Infect Dis 406, 1-8.
  25. Sridhar S, Luedtke A, Langevin E, et al (2018). Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med 379, 327-40.
  26. Swaminathan S, Khanna N (2019). Dengue vaccine development: Global and Indian scenarios. Int J Infect Dis 84, 80-86.
  27. Tricou V, Sáez-Llorens X, Yu D, et al (2020). Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: A randomised, placebo-controlled, phase 2 trial. Lancet 395, 1434-1443.
  28. Waickman AT, Friberg H, Gargulak M, et al (2019). Assessing the diversity and stability of cellular immunity generated in response to the candidate live-attenuated dengue virus vaccine TAK-003. Front Immunol 10, 1-13.
  29. Wang W, Nayim A, Chang MR, et al (2020). Dengue hemorrhagic fever: A systemic literature review of current perspectives on pathogenesis, prevention and control. J Microbiol Immunol Infect 53, 963-978.
  30. Whitehead SS (2016). Development of TV003 / TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi- Pasteur CYD TM vaccine? Expert Rev Vaccines 15, 509-517.
  31. Whitehead SS, Durbin AP, Pierce KK, et al (2017). In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. PLoS Negl Trop Dis 11, 1-19.
  32. Wilder-Smith A (2020). Dengue vaccine development: Status and future. Bundesgesundheitsblatt Gesund-heitsforsch Gesundheitsschutz 63, 40-4.
  33. World Health Organization (2014). Dengue and Severe Dengue. WHO Fact Sheet. Available from www.who.int. Accessed August 9, 2020.
  34. World Health Organization (2018). Revised SAGE Recommendation on Use of Dengue Vaccine. Available from: http://www.who.int. Accessed August 20, 2020.